Eli Lilly pointed to lower-dose and maintenance approaches for its obesity medicines, framing dose reduction as a potential option for sustaining weight loss while managing safety and cost considerations. The company highlighted data supporting weight loss maintenance after stepping down Zepbound and evaluating Foundayo as part of longer-term strategies. The reporting aligns with other evidence-generation efforts presented in obesity congress settings, where trials are increasingly designed to answer maintenance and durability questions rather than only initial weight reduction. For biotech and payers, the emerging focus is on how to match dose intensity to patient persistence, tolerability, and economic pressure—factors that shape access beyond branded induction dosing.